Summary annotation for rs3788189 (SLC19A1); pemetrexed; Carcinoma, Non-Small-Cell Lung and Mesothelioma (level 3 Efficacy)

Level of Evidence

Level 3Learn more about Summary Annotation Levels of Evidence(opens in new window)

Phenotype Category

Efficacy

Genes

SLC19A1

Variant

rs3788189

Drugs

pemetrexed

Phenotypes

Mesothelioma, Non-Small Cell Lung Carcinoma

ID

1444666803
AllelePhenotype
GGPatients with the GG genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.
GTPatients with the GT genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.
TTPatients with the TT genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence overall survival time.

Level of Evidence Calculation More information

Total Score
2
Score Breakdown
  • Variant Annotations = 2
  • Dosing Guideline Annotations = 0
  • Drug Label Annotations = 0
Level Modifiers
VIPLearn more about VIPs(opens in new window)
Calculated Level from Score
Level 3Learn more about Summary Annotation Levels of Evidence(opens in new window)

Evidence

  • 0 Dosing Guideline Annotations
  • 0 Drug Label Annotations
  • 1 Variant Annotation from 1 Publication
    • 1 Positive association Variant Annotation
    • 0 Negative association Variant Annotations

1. Annotation of rs3788189 in SLC19A1

Genotypes GG + GT is associated with decreased overall survival when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotype TT.

Advanced stage non-small-cell lung cancer (n=94), malignant mesothelioma (n=42). No association with progression-free survival was seen. Please note alleles have been complemented to the plus chromosomal strand.

From Publication

Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations. The pharmacogenomics journal. 2014. Corrigan A et al.
PMID:24732178(opens in new window) DOI:10.1038/tpj.2014.13(opens in new window)

Gene

SLC19A1

Variant

rs3788189

Phenotype Category

Efficacy

Association Significance

The study reports this association is significant

ID

1296666389

Score
More info on scoring

2

Study Parameters

Study type

cohort

Study size

136

Association p-value

= 0.026

Statistical analysis

HR: 1.71

Confidence interval

1.07 - 2.73

Allele frequency

T=0.533

Biogeographical group
More info on groups

Multiple groups, Caucasian, African, Asian, Other, Not stated

Population description

Drug: Pemetrexed/platinum doublet chemotherapy

History

Loading...